Document is current
Any future updates will be listed below
-
Authors
McIntosh, Owen D. https://orcid.org/0000-0001-5184-6055
Britchford, Emily R. https://orcid.org/0000-0002-7008-0718
Beeken, Lydia J.
Hopkinson, Andrew https://orcid.org/0000-0002-8801-7485
Sidney, Laura E. https://orcid.org/0000-0003-1466-7597
-
Funding
Funding for this research was provided by:
Medical Research Council (MC/PC/14102)
Engineering and Physical Sciences Research Council (EP/N00941X/1, EP/N00941X/1, EP/K503800/1)
- License Information
-
More Information
Article History
Received: 11 March 2024
Accepted: 13 December 2024
First Online: 9 January 2025
Declarations
:
: OM, LB and LS declare they have no relevant financial or non-financial interests to disclose. AH declares a relationship with NuVision Biotherapies Ltd, Nottingham that includes employment and equity or stocks. EB declares a relationship with NuVision Biotherapies Ltd, Nottingham that includes employment.
: Anonymised human corneas surplus to transplant requirement were obtained from SightLife (now CorneaGen, Seattle, WA, USA) under a materials transfer agreement. All work was performed in a laboratory under a research license from the UK Human Tissue Authority, UK. Informed consent was obtained from donors/relative prior to collection. Institutional ethical approval was not required as samples arrived anonymised, and consent was held at SightLife.
